Q1 Earnings Estimate for CorMedix Issued By Leerink Partnrs

CorMedix Inc. (NASDAQ:CRMD) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for CorMedix in a report released on Tuesday, March 25th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn $0.23 per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.73 EPS, FY2026 earnings at $2.50 EPS, FY2027 earnings at $3.20 EPS and FY2028 earnings at $3.65 EPS.

Other research analysts have also issued research reports about the stock. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price target on shares of CorMedix in a research note on Tuesday. Needham & Company LLC cut their price objective on shares of CorMedix from $18.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday. Leerink Partners assumed coverage on CorMedix in a research note on Friday, March 7th. They set an “outperform” rating and a $18.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $12.00 target price on shares of CorMedix in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

CorMedix Stock Performance

Shares of NASDAQ:CRMD opened at $6.71 on Friday. The company has a 50-day simple moving average of $10.54 and a 200 day simple moving average of $9.88. The company has a market capitalization of $407.14 million, a P/E ratio of -8.28 and a beta of 1.53. CorMedix has a 52-week low of $3.61 and a 52-week high of $13.85.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Tuesday, March 25th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.05. The company had revenue of $30.00 million during the quarter, compared to the consensus estimate of $27.46 million. The business’s revenue for the quarter was up 29900.0% on a year-over-year basis.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. FMR LLC lifted its position in CorMedix by 54.3% in the 3rd quarter. FMR LLC now owns 4,618 shares of the company’s stock valued at $37,000 after acquiring an additional 1,625 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of CorMedix in the fourth quarter valued at approximately $81,000. Captrust Financial Advisors bought a new position in shares of CorMedix in the fourth quarter valued at approximately $90,000. Aigen Investment Management LP purchased a new position in shares of CorMedix during the fourth quarter valued at approximately $94,000. Finally, XTX Topco Ltd bought a new stake in CorMedix during the fourth quarter worth $95,000. 34.18% of the stock is currently owned by institutional investors and hedge funds.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.